

## DAFTAR PUSTAKA

1. Lee N, Nguyen H. Ethambutol. StatPearls. 2023. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/16710500>
2. Kementerian Kesehatan Republik Indonesia. Tuberculosis Control in Indonesia 2022. In: Factsheet Country Profile Indonesia 2022 [Internet]. 2022. p. 1–48. Available from: <https://tbindonesia.or.id/wp-content/uploads/2023/02/Factsheet-Country-Profile-Indonesia-2022.pdf>
3. Chamberlain PD, Sadaka A, Berry S, Lee AG. Ethambutol opticneuropathy. *Curr Opin Ophthalmol* [Internet]. 2017 Nov;28(6):545–51. Available from: <https://journals.lww.com/00055735-201711000-00002>
4. Juzmi NA, Umar BT, Taufik R. NEUROPATI OPTIK TOKSIK SETELAH PEMBERIAN ETAMBUTOL PADA PENDERITA TUBERKULOSIS DI MAKASSAR. *JST Kesehat*. 2014;4(3):269–76.
5. Cao Z, Sun C, Wang W, Zheng X, Wu J, Gao H. Multi-modality fusion learning for the automatic diagnosis of optic neuropathy. *Pattern Recognit Lett* [Internet]. 2021 Feb;142:58–64. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0167865520304402>
6. Irma J, Kartika A, Rini M, Setiohadji B, Salim J. A Protective Role of Coenzyme Q10 in Ethambutol-Induced Retinal Ganglion Cell Toxicity: A Randomised Controlled Trial in Mice. *Neuroophthalmology* [Internet]. 2022;46(5):298–303. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/36337227>
7. Iulia C., Ruxandra T., Costin LB., Liliana-Mary V., Chitu I., Tudosescu R., et al. Citicoline—A neuroprotector with proven effects on glaucomatous disease. *Rom J Ophthalmol*. 2017;61,:152–158.
8. Jasielski P, Piędel F, Piwek M, Rocka A, Petit V, Rejdak K. Application of citicoline in neurological disorders: A systematic review. *Nutrients*. 2020;12(10):1–20.
9. Sen S, Mandal S, Banerjee M, Gk R, Saxena A, Aalok SP, et al. Ethambutol-induced optic neuropathy: Functional and structural changes in the retina and optic nerve. *Semin Ophthalmol* [Internet]. 2022;37(6):730–9. Available from: <https://doi.org/10.1080/08820538.2022.2085517>
10. Şahin A, Kürşat CA, Kaya S, Türkcü G, Arı Ş, Evliyaoğlu O, et al. The protective effects of caffeic acid phenethyl ester in isoniazid and ethambutol-induced ocular toxicity of rats. *Cutan Ocul Toxicol*. 2013;32(3):228–33.
11. Saxena R, Singh D, Phuljhele S, Kalaiselvan V, Karna S, Gandhi R, et al. Ethambutol toxicity: Expert panel consensus for the primary prevention, diagnosis and management of ethambutol-induced optic neuropathy. *Indian Ophthalmol* [Internet]. 2021 Dec;69(12):3734–9. Available from:

<http://www.ncbi.nlm.nih.gov/pubmed/34827033>

12. World Health Organization. Ethambutol efficacy and toxicity : literature review and recommendations for daily and intermittent dosage in children. World Health Organ [Internet]. 2006; Available from: [http://www.who.int/maternal\\_child\\_adolescent/documents/htm\\_tb\\_2006\\_365/en/index.html#.UHNzke\\_kFCg.mendeley](http://www.who.int/maternal_child_adolescent/documents/htm_tb_2006_365/en/index.html#.UHNzke_kFCg.mendeley)
13. Nusanti S, Sari RI, Siregar NC, Sidik M. The Effect of Citicoline on Ethambutol Optic Neuropathy: Histopathology and Immunohistochemistry Analysis of Retina Ganglion Cell Damage Level in Rat Model. *J Ocul Pharmacol Ther* [Internet]. 2022 Oct 1;38(8):584–9. Available from: <https://www.liebertpub.com/doi/10.1089/jop.2022.0005>
14. Rötig A., Appelkvist EL., Geromel V., Chretien D., Kadhom N., Edery P., et al. Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. *Lancet*. 3<sup>56</sup>,:391–5.
15. Mollet J., Giurgea I., Schlemmer D., Dallner G., Chretien D., Delahodde A., et al. Prenyldiphosphate synthase, subunit 1 (PDSS1) and OH-benzoate polyprenyltransferase (COQ2) mutations in ubiquinone deficiency and oxidative phosphorylation disorders. *J Clin Investig*. 117,:765–72.
16. Desbats MA., Morbidoni V., Silic-Benussi M., Doimo M., Ciminale V., Cassina M., et al. The COQ2 genotype predicts the severity of coenzyme Q10 deficiency. *Hum Mol Genet*. 25,:4256–65.
17. Blasi MA., Bovina C., Carella G., Genova ML., Jansen AM., Lenaz G., et al. Does coenzyme Q10 play a role in opposing oxidative stress in patients with age-related macular degeneration? *Ophthalmologica*. 215,:51–54.
18. Lim SA. Ethambutol-associated optic neuropathy. *Ann Acad Med Singapore*. 2006 Apr;35(4):274–8.
19. Palomino J, Martin A. Drug Resistance Mechanisms in Mycobacterium tuberculosis. *Antibiot (Basel)*. 3(3):317-40
20. Zhu C, Liu Y, Hu L, Yang M, He Z. Molecular mechanism of the synergistic activity of ethambutol and isoniazid against Mycobacterium tuberculosis. *J Biol Chem*. 293(43):16741-50.
21. Abbasinazari M, Kobarfard F, Tabarsi P, Maryam A, Salamzadeh J. Effect of Antituberculosis Regimen Containing Ethambutol on Serum magnesium Level in Pulmonary Tuberculosis Patients. *Iran J Pharm Res*. 2009;8.
22. Donald P, Maher D, Maritz J, Qazi S. Ethambutol dosage for the treatment of children: literature review and recommendations. *Int J Tuberc Lung Dis*. 10(12):1318–30.
23. Jeong I, Park J, Cho Y, Yoon H, Song J, Lee C, et al. Drug-induced

- hepatotoxicity of anti-tuberculosis drugs and their serum levels. *J Korean Med Sci*. 30(2):167–72.
24. Sidik dkk. Neuropati optik toksik etambutol. In : *Neuro Oftalmologi pada praktek sehari-hari*. INANOS. 2021 .p49
  25. [Internet]. World Health Organization. 2023. Available from: [https://www.who.int/news-room/fact-sheets/detail/tuberculosis#:~:text=Worldwide%2C TB is the 13th,all countries and age groups](https://www.who.int/news-room/fact-sheets/detail/tuberculosis#:~:text=Worldwide%2C%20TB%20is%20the%2013th,all%20countries%20and%20age%20groups).
  26. Chen HY, Lai SW, Muo CH, Chen PC, Wang IJ. Ethambutol-induced optic neuropathy: a nationwide population-based study from Taiwan. *Br J Ophthalmol* [Internet]. 2012 Nov;96(11):1368–71. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22960095>
  27. Mustak H, Rogers G, Cook C. Ethambutol induced toxic optic neuropathy in HIV positive patients. *Int J Ophthalmol* [Internet]. 2013;6(4):542–5. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23991394>
  28. Wang MY, Sadun AA. Drug-Related Mitochondrial Optic Neuropathies. *J Neuro-Ophthalmology* [Internet]. 2013 Jun;33(2):172–8. Available from: <https://journals.lww.com/00041327-201306000-00019>
  29. Heng J, Vorwerk C, Lessell E, Zurakowski D, Levin L, Dreyer E. Ethambutol is toxic to retinal ganglion cells via an excitotoxic pathway. *Invest Ophthalmol Vis Sci*. 40(1):190–6.
  30. Sadun AA, Wang MY. Ethambutol optic neuropathy: How we can prevent 100,000 new cases of blindness each year. *J Neuro-Ophthalmology*. 2008;28(4):265–8.
  31. Becker DA, Balcer LJ, Galetta SL. The Neurological Complications of Nutritional Deficiency following Bariatric Surgery. *J Obes* [Internet]. 2012;2012:1–8. Available from: <http://www.hindawi.com/journals/job/2012/608534/>
  32. Kinoshita J, Iwata N, Maejima T, Kimotsuki T, Yasuda M. Retinal Function and Morphology in Monkeys with Ethambutol-Induced Optic Neuropathy. *Investig Ophthalmology Vis Sci* [Internet]. 2012 Oct 9;53(11):7052. Available from: <http://iovs.arvojournals.org/article.aspx?doi=10.1167/iovs.12-10308>
  33. Leibold JE. THE OCULAR TOXICITY OF ETHAMBUTOL AND ITS RELATION TO DOSE. *Ann N Y Acad Sci* [Internet]. 1966 Apr;135(2 NewAntituber):904–9. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/j.1749-6632.1966.tb45532.x>
  34. KERRISON J. Optic neuropathies caused by toxins and adverse drug reactions. *Ophthalmol Clin North Am* [Internet]. 2004 Sep;17(3):481–8. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0896154904000380>

35. Behera C, Krishna K, Singh H. Antitubercular drug-induced violent suicide of a hospitalised patient. *BMJ* 2011;343(7827):e1000. doi:10.1136/bmj.e1000.
37. Kim K, Park S. Visual function test for early detection of ethambutol-induced ocular toxicity at the subclinical level. *Cutan Ocul Toxicol*. 35(3):228–32.
38. Crane F. Biochemical functions of coenzyme Q10. *J Am Coll Nutr*. 2001;20:591–8.
39. Manzar H, Abdulhusein D, Yap TE, Cordeiro MF. Cellular consequences of coenzyme q10 deficiency in neurodegeneration of the retina and brain. *Int J Mol Sci*. 2020;21(23):1–13.
40. Choi CH, Kim SH, Shanmugam S, Baskaran R, Park JS, Yong CS, et al. Relative Bioavailability of Coenzyme Q10 in Emulsion and Liposome Formulations. *Biomol Ther - BIOMOL THER*. 2010;18:99–105.
41. Silverman HM., Romano J., Elmer G. The Vitamin Book. In: Bantam Books: New York; 1993.
42. Acosta MJ., Fonseca LV., Desbats MA., Cerqua C., Zordan R., Trevisson E., et al. Coenzyme Q biosynthesis in health and disease. *Biochim Biophys Acta (BBA)-Bioenerg*. 1857;:1079–85.
43. Nohl H., Gille L. The role of coenzyme Q in lysosomes. In: *Coenzyme Q: Molecular Mechanisms in Health and Disease*. Boca Raton: CRC Press; 2001. p. 99–106.
44. Echtay K, Winkler E, Klingenberg M. Coenzyme Q is an obligatory cofactor for uncoupling protein function. *Nature*. 2000;408:609–13.
45. Qu J, Kaufman Y, Washington I. Coenzyme Q10 in the human retina. *Investig Ophthalmol Vis Sci*. 2009;50(4):1814–8.
46. National Center for Biotechnology Information . Coenzyme Q10 |Compound Summary. Bethesda: National Center for Biotechnology Information; 2005.
47. De Barcelos IPD., Haas RH. CoQ10 and ageing. *Biology (Basel)*. 8;:28.
48. Aguilaniu H, Durieux J, Dillin A. Metabolism, ubiquinone synthesis, and longevity. *Genes Dev*. 2005;19:2399–406.
49. Hernández-Camacho JD, Bernier M, López-Lluch G, Navas P. Coenzyme Q10 Supplementation in Aging and Disease. *Front Physiol* [Internet]. 2018 Feb 5;9. Available from: <http://journal.frontiersin.org/article/10.3389/fphys.2018.00044/full>

50. Schniertshauer D, Müller S, Mayr T, Sonntag T, Gebhard D, Bergemann J. Accelerated Regeneration of ATP Level after Irradiation in Human Skin Fibroblasts by Coenzyme Q 10. *Photochem Photobiol* [Internet]. 2016 May;92(3):488–94. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/php.12583>
51. Mancini A., Festa R., Raimondo S., Pontecorvi A. \, Littarru GP. Hormonal influence on coenzyme Q10 levels in blood plasma. *Int J Mol Sci.* 12,:9216–25.
52. Di Mauro S., Quinzii CM., Hirano M. Mutations in coenzyme Q 10 biosynthetic genes. *J Clin Investig.* 117,:587–9.
53. Miles MV., Horn PS., Morrison JA., Tang PH., De Grauw T., Pesce AJ. Plasma coenzyme Q10 reference intervals, but not redox status, are affected by gender and race in self-reported healthy adults. *Clin Chim Acta.* 332,:123–32.
54. Quinzii CM., López LC., Gilkerson RW., Dorado B., Coku J., Naini AB., et al. Reactive oxygen species, oxidative stress, and cell death correlate with level of CoQ10 deficiency. *FASEB J.* 24,:3733–43.
55. Quinzii CM., Luna-Sanchez M., Ziosi M., Hidalgo-Gutierrez A., Kleiner G., Lopez LC. The role of sulfide oxidation impairment in the pathogenesis of primary CoQ deficiency. *Front Physiol.* 8,:525.
56. Lagendijk J., Ubbink JB., Vermaak WJ. Measurement of the ratio between the reduced and oxidized forms of coenzyme Q10 in human plasma as a possible marker of oxidative stress. *J Lipid Res.* 37,:67–75.
57. Jamboua R, El-Assaada F, Combes V, Grau GE. Citicoline (CDP-choline): What role in the treatment of complications of infectious diseases. *Int J Biochem Cell Biol.* 2009;41(2009):1467–70.
58. Roohi-Azizi M., Arabzadeh S., Amidfar M., Salimi S., Zarindast MR., Talaei A., et al. Citicoline Combination Therapy for Major Depressive Disorder. *Clin Neuropharmacol.* 40,:1–5.
59. Grieb P. Neuroprotective Properties Of Citicoline: Facts, Doubts And Unresolved Issues. *Current Opinion.* In: *Citicoline for Neuroprotection.* Adis: CNS Drugs; 2014. p. 185–93.
60. Oddone F, Rossetti L, Parravano M, Sbardella D, Coletta M, Ziccardi L, et al. Citicoline in ophthalmological neurodegenerative disease: A comprehensive review. *Pharmaceuticals.* 2021;14(3):1–26.
61. Kim US, Mahroo OA, Mollon JD, Yu-Wai-Man P. Retinal Ganglion Cells—Diversity of Cell Types and Clinical Relevance. *Front Neurol.* 2021;12(2021):1–20.
62. Sheng WY, Su LY, Ge W, Wu SQ, Zhu LW. Analysis of structural injury

patterns in peripapillary retinal nerve fibre layer and retinal ganglion cell layer in ethambutol-induced optic neuropathy. *BMC Ophthalmol.* 2021;21:132.

63. Dutta S, Sengupta P. Human and mice: Relating their ages. *Life Sci.* 2016;152:244–8.
64. Nelandriani, Sutarya E, Bambang S. Suplementasi Zinc dan Densitas Sel Ganglion Retina Tikus yang Diberi Etambutol. *Majalah Kedokteran Bandung.* 2012
65. Nair A, Jacob S. A simple practice guide for dose conversion between animals and human. *J Basic Clin Pharm.* 2016;7(2):27.
66. Kartika A, Sri A, Setiohadji. Retinal Ganglion Cell Density after Coenzyme Q10 Treatment in a rat model of Methanol Toxic Optic Neuropathy. 2017
67. Parisi et al. Citicoline and RGC : Effects and Morphology and Functions. *Neuropharmacol.* 2018.
68. Frank et al. Citicoline and lithium rescue retinal ganglion cells following partial optic nerve crush in rat. 2016
69. Sitepu dkk. Efek Neurotropik dari Pemberian Koenzim Q10, Curcumin dan Metilprednisilon terhadap densitas sel agnglion retina pada tikus model neuropati optik toksis akibat metanol.

